A study by Thermo Fisher Scientific and the Tufts Center for the Study of Drug Development indicates that integrated contract research and manufacturing solutions can shorten oncology drug development timelines by up to 34 months. The study identifies reduced 'white space'—downtime between clinical trial phases—as the key factor, enabled by consolidated oversight and streamlined decision-making with a single vendor platform. While focused on cancer therapies, the approach shows promise for broader pharmaceutical modalities, potentially accelerating new drug introductions industry-wide.